Other formats:
BibTeX
LaTeX
RIS
@article{1883018,
author = {Hussain, Mohammad Salman and Klugarová, Jitka and Klugar, Miloslav},
article_location = {Clare},
article_number = {August 170},
doi = {http://dx.doi.org/10.1016/j.lungcan.2022.06.002},
keywords = {Cost-effectiveness; Durvalumab; Lung cancer; Non-small-cell lung cancer; NSCLC; Systematic review},
language = {eng},
issn = {0169-5002},
journal = {Lung Cancer},
title = {Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC},
url = {https://www.sciencedirect.com/science/article/pii/S0169500222004664},
volume = {170},
year = {2022}
}
TY - JOUR
ID - 1883018
AU - Hussain, Mohammad Salman - Klugarová, Jitka - Klugar, Miloslav
PY - 2022
TI - Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC
JF - Lung Cancer
VL - 170
IS - August 170
SP - 11-19
EP - 11-19
PB - Elsevier Ireland Ltd.
SN - 01695002
KW - Cost-effectiveness
KW - Durvalumab
KW - Lung cancer
KW - Non-small-cell lung cancer
KW - NSCLC
KW - Systematic review
UR - https://www.sciencedirect.com/science/article/pii/S0169500222004664
N2 - Background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Recently, Durvalumab was approved as a potential immunotherapy for the management of unresectable stage III NSCLC. Economic studies from different parts of the world presented varying findings. Therefore, the objective of this study was to assess the cost-effectiveness of durvalumab consolidation therapy versus no consolidation therapy in patients with unresectable stage III NSCLC. Methods PubMed, Embase, and Cochrane databases were searched till March 2022 to identify all the studies assessing the economic evaluation of durvalumab in patients with unresectable stage III NSCLC who had not progressed after chemoradiotherapy. Eligible studies were screened by two reviewers independently and the quality of included studies was evaluated using the updated version of Consolidated Health Economic Evaluation Reporting Standards (CHEERS 2022) checklists. All costs were converted to 2022 US dollars ($) by adjusting for the gross domestic product (GDP) deflator index and purchasing power parities for GDP. Results A total of seven studies were found to be eligible for inclusion. The majority of studies were conducted in the US (n = 3), while one study each was conducted in China, Italy, Switzerland, and the UK. The healthcare payers’ perspective was most commonly observed among the included studies and the time horizon varied from 5 years to a lifetime. Three studies received funding from Industry. Four included studies used the Markov model, while two employed the semi-Markov model and, one study used decision-analytic model. The ICER of durvalumab consolidation therapy in the US was found to be in the range of $59,850 to $145,543 per Quality-Adjusted Life Years (QALY). Likewise, the ICER of durvalumab in European countries ranged from $62,021 to $76,068 per QALY. The ICER was below the implemented country-specific willingness-to-pay thresholds in all the included studies. Conclusion Durvalumab consolidation therapy was found to be cost-effective compared to no consolidation therapy after chemoradiotherapy in stage-III NSCLC patients.
ER -
HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ and Miloslav KLUGAR. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC. \textit{Lung Cancer}. Clare: Elsevier Ireland Ltd., 2022, vol.~170, August 170, p.~11-19. ISSN~0169-5002. Available from: https://dx.doi.org/10.1016/j.lungcan.2022.06.002.
|
